China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...
HKG: 0512
China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...
China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization...
China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...
China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report...
Grand Pharmaceutical’s GSP301 NS Meets Primary Endpoint in Phase III SAR Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Phase III study (GSP...
Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...
Grand Pharmaceutical Group Initiates Phase I Study for Sepsis Treatment APAD
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the...
Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...
Grand Pharmaceutical Group Gets NMPA Approval for Generic Eplerenone for Hypertension
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...
Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...
Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...
Grand Pharmaceutical’s STC3141 Achieves Clinical Endpoint in Sepsis Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib REFINE study...
SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements
The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...
Grand Pharmaceutical’s Novasight Hybrid System Receives Marketing Approval in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a...
Grand Pharmaceutical Group Files NDA for Ophthalmic Analgesic APP13007 with US FDA
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the filing of a New Drug...
Grand Pharmaceutical Group Completes Enrollment in Phase III Study for Ryaltris Nasal Spray
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the completion of all subject enrollment...
Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...
Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study...
OncoSec Medical’s TAVO-EP Combo Misses Primary Endpoint in Melanoma Trial
US-based OncoSec Medical Inc., (OTCMKTS: ONCSQ), majority-owned by China-based Grand Pharmaceutical Group Ltd (HKG: 0512),...